Thus, while CD8+ T cells target and eliminate tumor cells, the collaborative dynamics with CD4+ T cells are indispensable, underscoring the need for therapeutic strategies that harness the synergistic potential of both T cell subsets to maximize cancer immunotherapy efficacy. The gene discussed is CD8A; the disease is neoplasm.